|Over a week ago|
Cyteir Therapeutics initiated with an Overweight at JPMorgan » 08:3807/1307/13/21
JPMorgan analyst Anupam…
JPMorgan analyst Anupam Rama initiated coverage of Cyteir Therapeutics with an Overweight rating and $30 price target. The rating is based on the long term potential of the company's lead asset CYT-0851, a first in class RAD51-mediated homologous recombination inhibitor, Rama tells investors in a research note. Data last month showed early signals of activity and a clean safety profile with CYT-0851, which helps validate the program's synthetic lethality / DNA damage response approach, says the analyst.
BofA starts Cyteir Therapeutics at Buy with $23 price target » 07:4507/1307/13/21
As previously reported,…
As previously reported, BofA analyst Tazeen Ahmad initiated coverage of Cyteir Therapeutics with a Buy rating and $23 price target. Lead asset CYT0851 can "potentially develop into a pipeline in a product," said Ahmad, noting that it has shown broad activity across various cancer types in preclinical studies. Given development is early, Ahmad is looking toward several data updates on efficacy, safety and duration of effect to better measure 0851's "competitiveness in a diverse landscape of oncology medications," the analyst added.
Cyteir Therapeutics initiated with an Outperform at Wedbush » 07:3807/1307/13/21
Wedbush analyst Robert…
Wedbush analyst Robert Driscoll initiated coverage of Cyteir Therapeutics with an Outperform rating and $40 price target. The analyst highlights that Cyteir's lead program CYT-0851 inhibits a critical DNA repair pathway, homologous recombination, and is designed to exploit the key dependence of cancer cells on this pathway. Driscoll believes the clinical data generated thus far indicate significant potential for CYT-0851 as monotherapy across a wide variety of tumor types. Moreover, he expects Cyteir to leverage the wide therapeutic index demonstrated to date to broaden clinical development in combination with standard of care chemotherapies and targeted agents such as PARP inhibitors, allowing significant potential upside in earlier settings and additional tumor types.
Cyteir Therapeutics initiated with an Overweight at Morgan Stanley » 06:2807/1307/13/21
Morgan Stanley analyst…
Morgan Stanley analyst Jeffrey Hung initiated coverage of Cyteir Therapeutics with an Overweight rating and $33 price target. Cyteir is developing inhibitors to target cancers overexpressing DNA damaging genes and its initial human data are "encouraging," Hung tells investors. The company's lead drug candidate, CYT-0851, is expected to begin a Phase 2 monotherapy study and a Phase 1/2 combination study with standard of care therapies later this year, Hung noted.
Cyteir Therapeutics initiated with a Buy at BofA » 06:0307/1307/13/21
BofA initiated coverage…
BofA initiated coverage of Cyteir Therapeutics with a Buy rating and $23 price target.
Opening Day: Moving iMage moves up on market debut » 08:1207/1007/10/21
SNTG, RNAZ, AGRI, MITQ, LDOC, DIDI, BABA, CYT, FEMY, DNAY, AMAM, TRMR, ATAI, IPSC, VERV, LYEL, ISPC, HOOD, RGCB, QNIU, CMSL, SPRK, BLND, SCAN, VTEX, GAMB, DUOL, AUTH, RXST
Shares of Moving iMage…
|Over a month ago|
Fly Intel: After-Hours Movers » 18:2506/2906/29/21
POWW, VOXX, CYT, QUMU, AVAV, ALT, ANGN, REPX, GDYN, CERE, MDB
Check out this evening's…
RA Capital reports 9.4% passive stake in Cyteir Therapeutics » 16:3506/2906/29/21
RA Capital disclosed a…
RA Capital disclosed a 9.4% stake in Cyteir Therapeutics, which represents over 3.24M shares. The filing does not allow for activism.
Cyteir Therapeutics Inc trading resumes 09:4606/2506/25/21
Cyteir Therapeutics Inc trading halted, volatility trading pause 09:3606/2506/25/21